SGTX
Income statement / Annual
Last year (2022), Sigilon Therapeutics, Inc.'s total revenue was $12.94 M,
an increase of 34.85% from the previous year.
In 2022, Sigilon Therapeutics, Inc.'s net income was -$43.46 M.
See Sigilon Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$12.94 M
|
$9.60 M
|
$13.37 M
|
$14.16 M
|
$4.64 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$12.94 M |
$9.60 M |
$13.37 M |
$14.16 M |
$4.64 M |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$37.63 M
|
$65.07 M
|
$53.49 M
|
$48.11 M
|
$21.04 M
|
| General & Administrative
Expenses |
$18.98 M
|
$20.17 M
|
$12.53 M
|
$10.17 M
|
$6.67 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.98 M
|
$20.17 M
|
$12.53 M
|
$10.17 M
|
$6.67 M
|
| Other Expenses |
$1.45 M |
$55,000.00 |
-$89,000.00 |
-$6,000.00 |
-$81,000.00 |
| Operating Expenses |
$56.61 M |
$85.24 M |
$66.02 M |
$58.28 M |
$27.71 M |
| Cost And Expenses |
$56.61 M |
$85.24 M |
$66.02 M |
$58.28 M |
$27.71 M |
| Interest Income |
$946,000.00 |
$258,000.00 |
$312,000.00 |
$1.06 M |
$698,000.00 |
| Interest Expense |
$2.29 M |
$1.99 M |
$1.20 M |
$650,000.00 |
$289,000.00 |
| Depreciation &
Amortization |
$2.40 M
|
$313,000.00
|
$223,000.00
|
$1.73 M
|
$374,000.00
|
| EBITDA |
-$41.27 M
|
-$75.32 M
|
-$52.42 M
|
-$42.40 M
|
-$22.08 M
|
| EBITDA Ratio |
-3.19 |
-7.85 |
-3.92 |
-3 |
-4.76 |
| Operating Income Ratio
|
-3.37
|
-7.88
|
-3.94
|
-3.12
|
-4.98
|
| Total Other
Income/Expenses Net |
$105,000.00
|
-$1.68 M
|
-$1.97 M
|
$198,000.00
|
$310,000.00
|
| Income Before Tax |
-$43.56 M |
-$77.31 M |
-$54.61 M |
-$43.93 M |
-$22.77 M |
| Income Before Tax Ratio
|
-3.37
|
-8.05
|
-4.08
|
-3.1
|
-4.91
|
| Income Tax Expense |
-$105,000.00 |
$925,000.00 |
$259,000.00 |
$644,000.00 |
$599,000.00 |
| Net Income |
-$43.46 M |
-$78.24 M |
-$54.87 M |
-$44.57 M |
-$22.77 M |
| Net Income Ratio |
-3.36 |
-8.15 |
-4.1 |
-3.15 |
-4.91 |
| EPS |
-1.34 |
-31.92 |
-22.67 |
-27.53 |
-18.85 |
| EPS Diluted |
-1.34 |
-31.92 |
-22.67 |
-27.53 |
-18.85 |
| Weighted Average Shares
Out |
$32.41 M
|
$2.45 M
|
$2.42 M
|
$1.62 M
|
$1.21 M
|
| Weighted Average Shares
Out Diluted |
$32.41 M
|
$2.45 M
|
$2.42 M
|
$1.62 M
|
$1.21 M
|
| Link |
|
|
|
|
|
